FDA Brief

Warning letters Drugs

FDA warning letter to

Simtra BioPharma Solutions

High riskIssued Mar 3Posted Mar 10Center for Drug Evaluation and Research (CDER)

FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.

What happened

FDA conducted an unannounced inspection of Simtra Deutschland GmbH in Halle/Westphalia, Germany, from September 18 to 26, 2025, and found significant CGMP violations in aseptic processing for sterile drugs. The letter cites repeated microbial recoveries from cleaning use points and environmental monitoring in ISO 5/RABS areas, manufacturing with barrier systems that had failed leak tests, fibers shedding from material in critical areas, and decontamination cycles with positive biological indicators. FDA said the company's responses did not adequately address the root causes.

What FDA found

  1. Aseptic processing areas had inadequate controls, including excessively long deadlegs in cleaning-fluid lines and repeated microbial recoveries at ISO 5 cleaning points and in RABS.

    21 CFR 211.42(c)(10)
  2. The company made drug batches using barrier systems that had failed pressure-decay leak tests without confirming integrity, and it could not locate raw integrity test data for one line.

    21 CFR 211.42(c)(10)
  3. Visible fibers shed from protective material in critical aseptic filling areas, and the replacement material was not evaluated for particle generation.

    21 CFR 211.42(c)(10)
  4. Decontamination cycles were inadequately validated; positive biological indicators occurred in nearly all validation cycles, but acceptance criteria still allowed many survivors.

    21 CFR 211.113(b)
  5. Validation allowed items to rest on the bottom of the chamber, creating occluded surfaces, and biological indicator locations were not adequately documented or justified.

    21 CFR 211.113(b)
  6. The company failed to adequately investigate repeated positive biological indicators and repeated a failed validation cycle without proper investigation.

    21 CFR 211.113(b)

What FDA wants

FDA asks Simtra to provide comprehensive assessments and CAPA plans for cleaning and disinfection, barrier-system integrity, contamination hazards, shedding material, and decontamination validation, and to respond in writing within 15 working days. FDA also recommends a teleconference to discuss the corrective actions.

Who should pay attention

  • drugmakers that rely on this site as a contract manufacturer for sterile products
  • companies that buy or distribute sterile drugs made at the Halle/Westphalia site
  • quality teams at aseptic fill-finish operations using RABS or barrier systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk